Effects of Poly(ADP-Ribose) Polymerase-1 Inhibition in a Neonatal Rodent Model
of Hypoxic-Ischemic Injury by Klöfers, Melanie et al.
Research Article
Effects of Poly(ADP-Ribose) Polymerase-1 Inhibition in
a Neonatal Rodent Model of Hypoxic-Ischemic Injury
Melanie Klöfers,1 Jules Kohaut,1 Ivo Bendix,1 Josephine Herz,1 Vinzenz Boos,2
Ursula Felderhoff-Müser,1 andMark Dzietko1
1Department of Pediatrics I, Neonatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
2Department of Neonatology, Charite´-Universita¨tsmedizin Berlin, Berlin, Germany
Correspondence should be addressed to Ursula Felderhoff-Mu¨ser; ursula.felderhoff@uk-essen.de
and Mark Dzietko; mark.dzietko@uk-essen.de
Received 26 January 2017; Revised 11 April 2017; Accepted 26 April 2017; Published 15 June 2017
Academic Editor: Sang Won Suh
Copyright © 2017 Melanie Klo¨fers et al.This is an open access article distributed under the Creative CommonsAttribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Hypoxia ischemia (HI) to the developing brain occurs in 1–6 in 1000 live births. Large numbers of survivors have
neurological long-term sequelae. However, mechanisms of recovery after HI are not understood and preventive measures or
clinical treatments are not effective. Poly(ADP-ribose) polymerase-1 is overactivated in response to ischemia. In neonatal mice
HI activates PARP-1 but its role in perinatal brain injury remains uncertain.Objective. Aim of this study was to explore the effect of
TES448 (PARP-1-inhibitor) and hypothermia after an ischemic insult. Design and Methods. 10-day-old Wistar rats underwent HI.
TES448 was given 10min, 3 hrs, and 6 hrs after hypoxia. Hypothermia was started 30min after HI and brains were dissected at P12.
Western blotting and histological staining were used to evaluate for degree of injury. Results. Protein expression of PARP-1 levels
was diminished after TES448 treatment. Cresyl violet and TUNEL staining revealed decreased injury in male rat pups following
TES448 and combined treatment. Female rats showed increased numbers of TUNEL-positive cells after combined therapy. TES448
inhibited microglia activation after hypoxic-ischemic injury. A cellular response including NeuN, Olig2, andMBP was not affected
by PARP-1-inhibition. Conclusions. Inhibition of PARP-1 and hypothermia lead to an alteration of injury but this effect is sexually
dimorphic.
1. Introduction
Despite significant progress in obstetrical and neonatal care,
hypoxic-ischemic encephalopathy remains a leading cause of
death and disability in children. In developed countries 1–6
per 1000 live-born children experience a hypoxic-ischemic
insult to the brain during the neonatal period leading to
significant life-long morbidity and mortality. Cerebral palsy,
epilepsy, and visual impairment as well as cognitive and
motor deficits are common neurological problems later in
life [1, 2]. The pathogenesis of perinatal brain injury is com-
plex, including gray and white matter structures to varying
degrees, and depends on gestational age and developmental
stage [3]. It has been shown in human imaging studies and
animal models that damage to the brain does not only occur
at the time of injury but continues to evolve over a period of
days to weeks [3]. But the mechanisms behind this evolution
of brain injury are not fully understood and the only recom-
mended therapeutic intervention is hypothermia treatment
[4, 5]. However, a substantial number of infants still suffer
from neurological problems despite cooling therapy. There-
fore, current research focuses on the development of neuro-
protective strategies with potential add-on effects to hypo-
thermia [6, 7]. Poly(ADP-ribose) polymerases are ubiqui-
tously detectable in cerebral cell nuclei. They are activated in
response to cellular stress and are involved inmultiple nuclear
mechanisms including DNA repair, regulation of transcrip-
tion, cell division control, and cell death mechanisms [8–
10]. PARP-1 is the most abundant isoform in the brain [11].
In pathological or stress conditions, PARP-1 is considerably
increased and leads to different types of cell death including
necrosis and caspase-independent mitochondrial membrane
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depolarization followed by the release of apoptosis-inducing
factor (AIF) [12]. Furthermore, PARP-1 formation can influ-
ence transcription factors, notably nuclear factor kappa B,
thereby promoting inflammation [13]. In the adult brain,
PARP-1 contributes to neuronal injury and activation of
microglia [14]. In a number of severe and acute diseases
such as stroke, neurotrauma, circulatory shock, and acute
myocardial infarction, activation of PARP-1 is detectable in
human tissue samples supporting the clinical application
of PARP-1 inhibition [14–16]. In the neonatal brain, it has
been shown that hypoxia ischemia triggers PARP-1 activation
[17, 18] and that disruption of the PARP-1 gene protects
the developing brain predominantly in males [19]. Recently,
the pharmacokinetics of a PARP-1 inhibitor (TES448, TES
Pharma, Corciano, Italy) has been significantly improved and
published data revealed a robust neuroprotective effect in an
adult rat stroke model [20]. The aim of our study was to
establish whether this PARP-1 inhibitor modulates hypoxic-
ischemic brain injury in the developing brain resembling
the clinical situation of birth asphyxia in the term infant
[21, 22].
2. Materials and Methods
2.1. Ethics Statement. All animal procedures complied with
the European Committee’s Council Directive and were per-
formed in accordance with the ethical guidelines of the
University Duisburg-Essen and the German Animal Welfare
Act. All procedures have been approved by the local animal
welfare committees.
2.2. Experimental Protocol. Hypoxia ischemia (HI) was
induced in 10-day-old Wistar rat pups through electrocoag-
ulation (high temperature cautery, 1200∘C, Bovie, USA) of
the left common carotid artery under isoflurane anesthesia
(2–5Vol%). After surgery, animals were returned to their
dams for a 60min recovery period followed by 120min of
hypoxia (8% oxygen and balance nitrogen) conducted in an
oxygen chamber (OxyCycler, Biospherix, USA). Body tem-
perature during hypoxia was maintained through a warming
mat (Harvard Apparatus, USA) set to 37∘C. Sham controls
underwent anesthesia and incision only. Weights were daily
monitored for 48 hrs. Animals per litter and experiment
were randomly attributed to treatment paradigms and exper-
imenters were blinded of interventions and data analysis. A
total of 169 animals underwent the HI procedure including
82 males and 87 female rat pups. Animals were divided into
following groups for histology: Sham+NaCl 𝑛 = 38, HI +NaCl
𝑛 = 37, HI + NaCl + HT 𝑛 = 21, HI + TES448 𝑛 = 30, and
HI + TES448 + HT 𝑛 = 16. For immunoblotting animals were
randomly selected as follows: Sham + NaCl 𝑛 = 8, HI + NaCl
𝑛 = 8, and HI + TES448 𝑛 = 11.
2.3. Cooling Protocol. Hypothermia (HT) treatment was
applied 30min after end of hypoxia for the duration of
4 hrs. Therefore, sham-operated and ligated rats were placed
on a custom-made hypothermia plate with temperature
control by water circulation (28∘C) with a goal of 32∘C
rectal temperature. Noncooled ratswere kept with their dam.
Body temperature was monitored in cooled and noncooled
animals with a rectal probe for neonatal rodents (RET-4,
Physitemp Instruments Inc., USA) connected to a digital
thermometer (TH-5, Physitemp Instruments Inc., USA).
Measurements were performed in 6 to 8 sentinel animals
per group right after end of hypoxia (0min) and 60, 120,
180, and 240min after end of hypoxia during cooling period.
These measurements were done in all 4 treatment groups to
ensure achievement of target rectal temperature or to monitor
normal body temperature in the noncooled rats (Supplemen-
tal Figure 1 in Supplementary Material available online at
https://doi.org/10.1155/2017/2924848).
2.4. Drug Administration Protocol. Animals were randomly
assigned to treatment groups and received either normal
saline or PARP-1 inhibitor (TES448). Before application,
TES448 was dissolved in normal saline to obtain three
different concentrations (0.3mg/ml), stirred with vortex-
mixing for 5min at room temperature. The final solutions
were filtered (syringe filter, 0.45 𝜇m Supormembrane, PALL
PharmAssure, Porsmouth, England). TES448was given at the
dose of 3, 10, and 20mg/kg, intraperitoneally; 10min, 3 hrs,
and 6 hrs after the end of hypoxia. Normal saline served as
the corresponding control and was injected at the same time
points to sham or HI animals.
2.5. Histological Scoring. Animals were deeply anesthetized
with chloral hydrate (200mg/kg bodyweight) 48 hrs after end
of HI and transcardially perfused with ice-cold phosphate
buffered saline (PBS) followed by 4% paraformaldehyde
(PFA, pH 7.4). After decapitation, brains were carefully
removed, postfixed over night at 4∘C, and then processed
to be embedded in paraffin. Using a microtome (Thermo-
Scientific, Walldorf, Germany), 10 𝜇m coronal sections were
cut and mounted onto glass slides. To determine acute brain
injury, adjacent paraffin sections were collected at the level of
+0.2–+0.48mm(striatum),−3.12–−3.36mm(hippocampus),
and −5.52–−5.76mm from bregma (posterior cortex) and
stained using cresyl violet. Brains were analyzed for degree
of injury, using 4 consecutive coronal sections at the striatal,
hippocampal, and posterior cortical levels, in a blinded fashion,
using a scoring system, as previously described [23]. Briefly,
8 regions (anterior, middle, and posterior cortex, CA1, CA2,
CA3, and dentate gyrus of the hippocampus, and striatum)
were graded on a scale of 0 to 3 with 0 = no injury, 1 = few
small areas of focal injury, 2 = multiples areas of focal injury,
and 3 = widespread injury with loss of architecture. These 8
regional scores were summed to provide a scale of 0 to 24
where 0 denotes no injury and 24 denotes severe injury with
cystic infarction.
2.6. Quantification of Cell Death. Degenerating cells were
determined in 10 𝜇m thick paraffin sections collected at the
hippocampal level (−3.12–−3.36mm from bregma) using
terminal deoxynucleotidyl transferase-mediated dUTP nick
end labelling (TUNEL). Staining was performed using the
In Situ Cell Death Detection Kit (Roche applied science,
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Table 1: Weight evolution after unilateral HI and TES448 treatment (HI versus sham controls, #𝑝 < 0.0001, ‡𝑝 < 0.001, ±SEM, and one-way
ANOVA with Bonferroni’s multiple-comparison test).
Sham + NaCl Sham + TES448 HI + NaCl HI + NaCl + HT HI + TES448 HI + TES448 + HT
Weight at P10 (g) 20.42 ± 0.5 20.99 ± 0.5 21.08 ± 0.4 24.5 ± 1.0 21.32 ± 0.8 25.6 ± 1.0
Weight at P12 (g) 24.78 ± 0.5 25.42 ± 0.9 21.09 ± 0.6 25.5 ± 1.6 21.82 ± 0.6 26.1 ± 1.4
Gained weight 122% ± 1.0 122.3% ± 2.1 100%# ± 2.0 104.1%‡ ± 4.1 103.4%# ± 2.7 102.3%# ± 4.5
Penzberg, Germany) according to manufacturer’s proto-
col. Sections were counterstained with 4,6-diamidino-2-
phenylindole (DAPI, 1 𝜇g/mL, Invitrogen, Karlsruhe, Ger-
many) and slides were mounted with Fluorescent Mounting
Medium and kept in the dark at 4∘C. Immunopositive cells
were counted manually in three regions of interest in the
parietal cortex and the entire hippocampus by an observer,
unaware of the treatment protocol, with an Axioplan fluores-
cent microscope (Zeiss, Jena, Germany) at 20x (cortex) and
10x (hippocampus) magnification (Supplemental Figure 2).
2.7. Western Blotting. For protein analysis, animals were
transcardially perfused with 0.1M PBS 48 hrs after end of
HI. After decapitation, brains were dissected, snap-frozen
in liquid nitrogen, and stored at −80∘C until analysis. Ipsi-
and contralateral hemispheres were homogenized in ice-
cold lysis buffer (RIPA, Sigma-Aldrich, Taufkirchen, Ger-
many) containing protease, phosphatase inhibitors (cOm-
plete, Roche), and 100mM PMSF (Sigma-Aldrich). Sam-
ples were centrifuged at 4∘C for 10min (3000×g) and the
supernatant (cytoplasmic and mitochondrial fraction) was
collected and recentrifuged at 17000×g for 20 minutes (4∘C).
The supernatant was collected (cytoplasmic fraction) fol-
lowed by determination of the protein concentration using
the Pierce BCA-protein assay kit (Thermo Scientific, USA).
The pellet (nuclear fraction) was washed with cold PBS
and again centrifuged at 3000×g for 10 minutes (4∘C). The
pellet (nuclear fraction) was rehomogenized with ice-cold
lysis buffer (RIPA, Sigma-Aldrich) followed by disruption of
the nucleus using an ultrasonicator (30 cycles each 30 sec
with 30 sec pause). Then the fraction was recentrifuged at
17000×g for 20min (4∘C) and protein concentrations were
determined in the supernatant. Forty micrograms of the
protein lysates were heat denaturated in Laemmli sample
loading buffer, separated by 8% sodium dodecyl sulfate
polyacrylamide gel electrophoresis, and electrotransferred
onto a nitrocellulose membrane (0.2 𝜇m, Amersham, USA)
at 4∘C overnight. Equal loading and transfer of proteins
were confirmed by staining the membranes with Ponceau
S solution (Fluka, Buchs, Switzerland). Nonspecific protein
binding was blocked by incubation in 5% nonfatmilk powder
and 0.1% Tween in TBS (TBST), followed by incubation
with the primary antibodies, anti-PARP (1 : 500; Santa Cruz
Biotechnology, Heidelberg, Germany), anti-Olig2 (1 : 2500;
Dako, Glostrup, Denmark), anti-NeuN (1 : 2000; Cell Sig-
naling), anti-MBP (1 : 2000; Cell Signaling), anti-Lamin B2
(1 : 5000; Abcam plc, Cambridge, UK), and anti-GAPDH
(1 : 1000, Santa Cruz Biotechnology). Membranes were then
incubated with the appropriate peroxidase-conjugated sec-
ondary antibodies at room temperature for 1 hr (anti-rabbit
1 : 2000 or anti-mouse 1 : 5000, Dako, Denmark) in blocking
solution followed by Chemiluminescent detection with the
ECL prime Western blotting detection reagent (Amersham,
GE Healthcare Life Science, USA). For visualization and
densitometric analysis the ChemiDocXRS+ imaging system
and ImageLab software (Bio-Rad, Germany) were used. All
plots were normalized to GAPDH or Lamin B2 and animals
were normalized to mean of the control group (Sham +
NaCl).
2.8. Statistical Analysis. Analysis was performed using
GraphPad Prism version 6.0 (GraphPad Software, La Jolla,
CA, USA). All results were expressed as box plots including
median values, the 25% and the 75% percentile. One-way
ANOVA with Bonferroni’s test post hoc analysis for multiple
comparisons or unpaired Student’s 𝑡-test as appropriate was
performed for statistical analysis. Statistical significance was
determined at 𝑝 < 0.05.
3. Results
3.1. Weight Evolution after Unilateral HI and Dose Response of
PARP-1 Inhibition. TES448 at a dose of 3mg/kg reduced injury
scoring followingHI.Higher doses (10 and 20mg/kg) resulted in
a lower degree or no protection afterHI. All further experiments
were conducted using 3mg/kg (Supplemental Figure 3). At
48 hrs following HI, there was a significant difference of
weight gain expressed by the ratio weight at P10/weight at
P12 between HI and sham-operated animals. Those weight
differences were not counteracted by PARP-1 inhibition or
hypothermia treatment (Table 1). No abnormal behavior like
convulsions and impaired or distinct activity was detected
after TES448 administration.
3.2. PARP-1 Levels Are Affected by InhibitorTherapy. Cerebral
PARP-1 levels were measured using Western blot to identify
effects of HI and TES448 treatment on the developing brain.
PARP-1 levels in the ipsilateral hemisphere were decreased in
TES448 treated HI animals (74.3 ± 8.8) compared to saline
treated HI animals (111 ± 14.4) 48 hrs after injury (Figure 1).
3.3. TES448 Treatment Modulates Histological Injury 48 hrs
after Unilateral HI. Whether HT and PARP-1 inhibition
provide early neuroprotection, brains were assessed by the
use of an injury score. Forty-eight hrs after HI, histolog-
ical changes were analyzed in the ipsilateral hemisphere
using cresyl violet stained coronal sections (Figure 2). We
detected increased brain injury predominantly in male ani-
mals exposed to HI and injected with saline (Figure 2(b)).
PARP-1 inhibition, hypothermia treatment, or a combined












































Figure 1: PARP-1 expression was analyzed in nuclear protein lysates
using the entire hemisphere of animals exposed to HI followed
by vehicle or TES448 treatment. A representative Western blot
image shows the expression of PARP-1 at 48 hrs after HI. Data are
normalized to sham animals (control = 100%, dashed line). Values
are presented as box plots including median values, the 25% and the
75% percentile (∗𝑝 < 0.05, unpaired Student’s 𝑡-test, 𝑛 = 8–11 per
group).
therapy provided no significant protection of the developing
brain (Figure 2). In addition, female rat pups showed no
significantly different injury scoring after a combined therapy
of cooling and TES448 compared to sham controls suggesting
a gender-specific sensitivity (Figure 2(c)). A detailed analysis
of brain regions (cortex and hippocampus) using histological
scoring revealed significant injury in male pups to the cortex
and hippocampus (Figures 3(a) and 3(c)). Hypothermia or
PARP-1 inhibition alone preceded not to significant brain
protection but a combined treatment reduced injury scoring
in the hippocampus of male pups to the level of sham
animals (Figure 3(a)). Females showed no significant brain
injury after HI in both regions of interest and a single or
combined treatment using hypothermia and TES448 provided
no significant histological recovery (Figures 3(b) and 3(d)).
Striatal tissue was not modulated in both genders by HI, HT,
TES448, or a combined therapy (data not shown).
3.4. A CombinedTherapy of PARP-1 Inhibition and Hypother-
miaDoesNot Affect Apoptotic Cell Death in theDeveloping Rat
Brain. In addition to cresyl violet staining we used TUNEL
as a marker of DNA breakdown and apoptotic cell death to
further evaluate degree of injury after TES448, cooling, or a
combined therapy 48 hrs after end of hypoxia in P12 rat pups.
Histological staining revealed increased neurodegeneration
after HI in the cortex and hippocampus (Figure 4(a), HI
+ NaCl). In age-matched sham littermates receiving vehicle,
degenerating cells were sparse (Figure 4(a), Sham + NaCl).
Imaging data suggest a reduction of TUNEL-positive cells
following PARP-1 inhibition and a combined therapy after HI
in the dentate gyrus (DG) in male animals (Figure 4(a), HI +
TES448 and HI + TES448 + HT). Nevertheless, significance
could not be determined following a combined quantification
in cortex and the entire hippocampus (Figure 4(b)) in male rat
pups. Furthermore, imaging data of TUNEL-positive cells in
female rat pups demonstrated an increase of TUNEL-positive
cells after a combined treatment (Figure 4(a), HI + TES448
+ HT female) suggesting a gender-dependent effect of PARP-1
inhibition and hypothermia but a significant difference between
males and females could not be determined in the HI + TES448
+ HT group (TUNEL (+) cells total: male: 630, 𝑛 = 5 versus
female: 1421, 𝑛 = 12; 𝑝 = 0.29, one-way ANOVA with
Bonferroni’s multiple-comparison test).
3.5. TES448 Induced PARP-1 Inhibition Modifies Cell Specific
Changes afterUnilateralHI. Tomore specifically differentiate
cell types most affected by HI and PARP-1 inhibition, we
performed Western blotting of NeuN, Olig2, MBP, and Iba-
1 as markers for neurons, oligodendrocytes, and microglial
activation. HI induced a detrimental reduction of neuronal
and oligodendrocytic markers in the ipsilateral hemisphere
48 hrs after hypoxia compare to sham animals. TES448 was
unable to counteract this effect efficiently (Figures 5(a) and
5(b)). MBP expression was not affected by HI or PARP-
1 inhibition (Figure 5(c)). The expression of Iba-1 protein
was used as a reflection of brain inflammatory response to
unilateral HI. Forty-eight hrs after hypoxia, we observed an
increased level of Iba-1 expression in the ipsilateral cerebral
hemisphere of animals injected with NaCl compared to sham
control pups. Animals receiving TES448 treatment after HI
reached the level of sham animals suggesting a modulatory
effect of PARP-1 inhibition on Iba-1 expression (Figure 5(d)).
4. Discussion
In our model of severe brain damage, we confirm that PARP-1
inhibition influences hypoxic-ischemic injury in P10 male rats,
modelling the clinical situation of birth asphyxia in the term
infant [21, 22]. This effect is sex-specific and preferentially
protects male rat pups following HI. In addition, we describe
that a single or combined therapy of hypothermia and
TES448 is insufficient in female rats to enhance histological
recovery. Our data are in general agreement that PARP-1
levels are modified following ischemic injury in young and
older animals [9, 11, 24]. It has been reported that different
types of PARP inhibitors or a disruption of the gene were
able to promote significant recovery in ischemic brain injury














































































































































Figure 2: P10 rats subjected to HI, treated with saline or TES448 and either cooled or kept with their dam, were analyzed 2 days after HI
to assess injury on cresyl violet stained sections. Values are presented as box plots including median values, the 25% and the 75% percentile,
∗∗𝑝 < 0.01, one-way ANOVA with Bonferroni’s multiple-comparison test, total 𝑛 = 16–38 per group, males 𝑛 = 5–19 per group, and females
𝑛 = 10–19 per group.
supporting the hypothesis that brain injury in the immature
brain depends on PARP-1 activation [17–20]. This effect
seems to be sexually dimorphic with male animal’s being
protected and with female rodent’s showing reduced protec-
tion after hypoxia ischemia [19, 20, 25, 26]. Similar to others
hypothermia alone conducted for 4 hrs did not demonstrate
neuroprotective effects in our model of severe injury [27–29].
This might be due to differences in mitochondrial physiology
or different DNA repair polymerases in females compared
to males. In addition, classical caspase-dependent apoptosis
appears to be more prevalent in females, who therefore receive
greater neuroprotective benefit from caspase inhibitors. The
predilection for caspase-independent cell death in males, as
in PARP-1 inhibition, may be due to decreased antioxidant
defenses and increased susceptibility to ROS and peroxyni-
trite production, stimulating both mitophagy and parthanatos

























































































































































































Figure 3: Histological analysis of brain regions (cortex and hippocampus) showed significant injury after HI. Hypothermia treatment (HT)
or PARP inhibition (TES448) alone leads not to significant brain protection but a combined treatment (HT + TES448) reduced injury scoring
in the hippocampus of male pups to the level of sham animals (a). In contrast, females were less severely injured after HI in the hippocampus
but a combined treatment using hypothermia and TES448 augmented brain injury although no significant difference was detected (b). Values
are presented as box plots including median values, the 25% and the 75% percentile, ∗𝑝 < 0.05, one-way ANOVAwith Bonferroni’s multiple-
comparison test, males 𝑛 = 5–19 per group, and females 𝑛 = 10–19 per group.
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Figure 4: TUNEL staining revealed increased neurodegeneration after HI in the dentate gyrus (DG) and cortex (Cx) compared to
sham controls receiving vehicle (a). Images of male animals receiving hypothermia (HT), TES448 only, or a combined therapy suggest a
neuroprotective effect of PARP inhibition and cooling therapy after HI (a) although statistical significance could not be determined (b).
Female rat pups demonstrated an increase of total TUNEL immunopositive cells after a combined treatment suggesting a gender-dependent
effect of PARP inhibition and hypothermia ((a) and (c)). Values of total TUNEL-positive cells are presented as box plots including median
values, the 25% and the 75% percentile, one-way ANOVA with Bonferroni’s multiple-comparison test, males 𝑛 = 5–11 per group, and females
𝑛 = 7–11 per group.
[30]. Nevertheless, protection induced by hypothermia is a
complicated, not completely understood process and con-
sensus on the best protocol in rodents still needs to be
determined. Experimental studies showed that hypothermia
induced immediately after moderate HI generates protection
[29, 31] but other groups provided evidence that hypothermia
itself does not promote recovery following severe HI [32].
A previous study in P10 mice with HI showed that male
animals are protected after hypothermia, while females had
variable degrees of injury and protective effects could not be
observed [27]. In addition, a combination of miscellaneous
drugs with hypothermia revealed conflicting results regard-
ing improved outcome after HI [33, 34], demonstrating that
limiting multiple pathophysiological mechanisms may be
needed to provide benefits. Furthermore, our results illustrate
that a combined therapy provides no additional benefit and
a simultaneous application may be used with caution if it
is translated into clinical settings. In our opinion, future
research should focus on stratification of degree of injury, with
treatment adjusted accordingly. With further investigation, it
may turn out that animals with severe encephalopathy would
derive greater benefits from drug treatments compared to
hypothermia. One potential limitation of the present study is
that due to technical limitations detrimental effects of hypo-
glycemia or a stress response to cooling could not be measured
or prevented raising the issue that potential compensatory
responses to cooling might interfere with the degree of injury.
Furthermore, short-term survival was analyzed only but in


























































































































































Figure 5: Protein expression of NeuN (a), Olig2 (b), MBP (c), and Iba-1 (d) was analyzed in protein lysates using the entire hemisphere
of animals exposed to HI followed by TES448 treatment. Hypoxic-ischemic injury triggered a decrease of NeuN and Olig2 but additional
TES448 therapy had no impact on protein expression. MBP expression was not affected by HI or PARP inhibition. Iba-1 expression was
increased in hypoxic-ischemic animals injected with NaCl compared to sham control pups. Animals receiving TES448 treatment after HI
reached the level of sham animals (d). Results are expressed as box plots including median values, the 25% and the 75% percentile, ∗𝑝 < 0.05,
∗∗𝑝 < 0.01, ∗∗∗∗𝑝 < 0.0001 one-way ANOVA with Bonferroni’s multiple-comparison test, and 𝑛 = 8–11 per group).
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comparison to the clinical setting; long-term improvements
in neurological outcome are the goal. In the used HI model,
certain short-term neuropathological markers do not always
predict long-term injury [28] and behavioral improvement
after neuroprotective treatment can be seen that are not reliably
predicted by histological injury [35]. As PARP-1 inhibition
did not sufficiently reduce histological damage after HI, we
analyzed specific brain regions known to respond differently
[36] and to be selectively vulnerable to HI [37]. Degree of
injury and protection by PARP-1 inhibition following HI
was most pronounced in the hippocampus in male animals
although the protective effect appears to be less robust
than in adult HI models. In contrary, the hippocampus of
females was not severely damaged following HI suggest-
ing that mechanisms that have been proposed to explain
neuroprotection obtained with PARP-1 inhibitors are not
regional equally expressed in both genders. It has been shown
that DNA lesions activate PARP-1 and cause excessive PAR
accumulation, the product of PARP-1 activity, and parallel the
time course of DNA damage following hypoxia ischemia in
the brain [38]. Imaging data using TUNEL staining reflecting
DNAbreakdowndepict a selective effect of PARP-1 inhibition
in male rat pups emphasizing that male animals solely may
benefit from treatment. Studies have provided evidence that
molecular mechanisms in response to activation of PARP
after experimental stroke are not identical in males and
females probably explaining selectivity of PARP inhibitors
[27]. It has been proposed that PARP-1-inhibitors are able to
interact with all cell types of the neurovascular unit including
the blood-brain barrier and to provide a better outcome
compared to other neuroprotective strategies so far tested
[9]. Therefore, we analyzed different cell types following HI
and provide evidence that the cellular response after PARP-
1 inhibition is diverse compared to the adult brain. We
confirmed a previously describe attenuation of NeuN and
MBP [31] after HI but TES448 was unable to counteract these
effects suggesting a different sensitivity of the developing
brain to PARP inhibition. The mechanism by which PARP-1-
inhibitors suppress inflammatory responses after brain injury
is not fully discovered but is likely to involve regulation of
proinflammatory transcription factors [39–41] andmicroglial
activation [12, 13]. Studies comparing juvenile and neonatal
mice revealed a stronger inflammatory response in neona-
tal pups following HI [36]. However, recent experimental
work using minocycline, a putative PARP inhibitor, inducing
microglial suppression revealed an age-dependent response
with neonatal animals showing improved histological and
behavioral outcome compared to older animals [42]. Simi-
larly, expression of Iba-1, a microglial marker, was prevented
in our animals treatedwith TES448 suggesting a contribution
of cerebral inflammation in the protective effects of PARP-1
inhibition. A recent review showed that immunomodulatory
therapies attenuating neuroinflammation provide effectivity
in experimental models supporting the use of immunomod-
ulating therapies in neonatal HI to prevent neuronal injury
[43]. Taken together, our results reveal that differences exist
between male and female brains after exposure to ischemic
injury and PARP-1 inhibition. These findings highlight the
challenges testing combined therapies but also provide an
opportunity for further investigation of therapy to prevent
injury from HI.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
Melanie Klo¨fers, Jules Kohaut, and Mark Dzietko per-
formed animal experiments and data analysis. Ivo Bendix,
Josephine Herz, Ursula Felderhoff-Mu¨ser, Vinzenz Boos, and
Mark Dzietko wrote the manuscript. Mark Dzietko and
Ursula Felderhoff-Mu¨ser designed and supervised the study.
Melanie Klo¨fers and Jules Kohaut contributed equally.
Acknowledgments
The authors gratefully thank Karina Kempe, Mandana Riza-
zad, Christian Koester, and Ralf Hermann for their excellent
technical assistance. This work was supported by a grant
from Chiesi Pharmaceutical Research and Development and
the Else Kro¨ner-Fresenius-Stiftung (ELAN), Bad Homburg,
Germany. The PARP inhibitor was provided by TES Pharma,
Corciano, Italy.
References
[1] N. Merchant and D. Azzopardi, “Early predictors of outcome
in infants treated with hypothermia for hypoxic-ischaemic
encephalopathy,” Developmental Medicine & Child Neurology,
vol. 57, no. 3, pp. 8–16, 2015.
[2] P. Eunson, “The long-term health, social, and financial bur-
den of hypoxic-ischaemic encephalopathy,” Developmental
Medicine and Child Neurology, vol. 57, no. 3, pp. 48–50, 2015.
[3] D. M. Ferriero, “Neonatal brain injury,” The New England
Journal of Medicine, vol. 351, no. 19, pp. 1985–1995, 2004.
[4] D. Azzopardi, B. Strohm, N. Marlow et al., “Effects of hypother-
mia for perinatal asphyxia on childhood outcomes,” The New
England Journal of Medicine, vol. 371, no. 2, pp. 140–149, 2014.
[5] S. E. Jacobs, M. Berg, R. Hunt,W. O. Tarnow-Mordi, T. E. Inder,
and P. G. Davis, “Cooling for newborns with hypoxic ischaemic
encephalopathy,”The Cochrane Database of Systematic Reviews,
vol. 1, Article ID CD003311, 2013.
[6] N. J. Robertson, S. Tan, F. Groenendaal et al., “Which neuro-
protective agents are ready for bench to bedside translation in
the newborn infant?” Journal of Pediatrics, vol. 160, no. 4, pp.
544.e4–552.e4, 2012.
[7] Y. W. Wu, A. M. Mathur, T. Chang et al., “High-Dose Erythro-
poietin and Hypothermia for Hypoxic-Ischemic Encephalopa-
thy: A Phase II Trial,” Pediatrics, vol. 137, no. 6, Article ID
e20160191, 2016.
[8] A. Chiarugi and M. A. Moskowitz, “Cell biology: PARP-1 - A
perpetrator of apoptotic cell death?” Science, vol. 297, no. 5579,
pp. 200-201, 2002.
[9] R. Zhang, S. Tang, W. Huang et al., “Protection of the brain
following cerebral ischemia through the attenuation of PARP-
1-induced neurovascular unit damage in rats,” Brain Research,
vol. 1624, pp. 9–18, 2015.
10 BioMed Research International
[10] R. P. Strosznajder, K. Czubowicz,H. Jesko, and J. B. Strosznajder,
“Poly(ADP-ribose) metabolism in brain and its role in ischemia
pathology,”Molecular Neurobiology, vol. 41, no. 2-3, pp. 187–196,
2010.
[11] F. Moroni, “Poly(ADP-ribose)polymerase 1 (PARP-1) and
postischemic brain damage,” Current Opinion in Pharmacology,
vol. 8, no. 1, pp. 96–103, 2008.
[12] A. Chiarugi and M. A. Moskowitz, “Poly(ADP-ribose) polym-
erase-1 activity promotes NF-𝜅B-driven transcription and
microglial activation: implication for neurodegenerative disor-
ders,” Journal ofNeurochemistry, vol. 85, no. 2, pp. 306–317, 2003.
[13] J. Xu, H. Wang, S. J. Won, J. Basu, D. Kapfhamer, and R. A.
Swanson, “Microglial activation induced by the alarmin S100B
is regulated by poly(ADP-ribose) polymerase-1,” GLIA, vol. 64,
no. 11, pp. 1869–1878, 2016.
[14] E. Gerace, D. E. Pellegrini-Giampietro, F. Moroni et al.,
“Poly(ADP-ribose)polymerase 1 (PARP-1) activation and Ca2+
permeable𝛼-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) channels in post-ischemic brain damage: New
therapeutic opportunities?” CNS and Neurological Disorders -
Drug Targets, vol. 14, no. 5, pp. 636–646, 2015.
[15] X. Tao, X. Chen, S. Hao et al., “Protective actions of PJ34,
a poly(ADP-ribose)polymerase inhibitor, on the blood-brain
barrier after traumatic brain injury in mice,” Neuroscience, vol.
291, pp. 26–36, 2015.
[16] N. J. Curtin and C. Szabo, “Therapeutic applications of PARP
inhibitors: anticancer therapy and beyond,” Molecular Aspects
of Medicine, vol. 34, no. 6, pp. 1217–1256, 2013.
[17] T.Neira-Pen˜a, E. Rojas-Mancilla, V.Munoz-Vio et al., “Perinatal
Asphyxia Leads to PARP-1 Overactivity, p65 Translocation,
IL-1𝛽 and TNF-𝛼 Overexpression, and Apoptotic-Like Cell
Death in Mesencephalon of Neonatal Rats: Prevention by Sys-
temic Neonatal Nicotinamide Administration,” Neurotoxicity
Research, vol. 27, no. 4, pp. 453–465, 2015.
[18] S. Ducrocq, N. Benjelloun, M. Plotkine, Y. Ben-Ari, and C.
Charriaut-Marlangue, “Poly(ADP-ribose) synthase inhibition
reduces ischemic injury and inflammation in neonatal rat
brain,” Journal of Neurochemistry, vol. 74, no. 6, pp. 2504–2511,
2000.
[19] H. Hagberg, M. A. Wilson, H. Matsushita et al., “PARP-1 gene
disruption in mice preferentially protects males from perinatal
brain injury,” Journal of Neurochemistry, vol. 90, no. 5, pp. 1068–
1075, 2004.
[20] F. Moroni, A. Cozzi, A. Chiarugi et al., “Long-lasting neu-
roprotection and neurological improvement in stroke models
with new, potent and brain permeable inhibitors of poly(ADP-
ribose) polymerase,” British Journal of Pharmacology, vol. 165,
no. 5, pp. 1487–1500, 2012.
[21] S. D. Patel, L. Pierce, A. Ciardiello et al., “Therapeutic hypother-
mia and hypoxia-ischemia in the term-equivalent neonatal rat:
Characterization of a translational preclinical model,” Pediatric
Research, vol. 78, no. 3, pp. 264–271, 2015.
[22] B. D. Semple, K. Blomgren, K. Gimlin, D. M. Ferriero, and L. J.
Noble-Haeusslein, “Brain development in rodents and humans:
identifying benchmarks of maturation and vulnerability to
injury across species,” Progress in Neurobiology, vol. 106-107, pp.
1–16, 2013.
[23] R. A. Sheldon, C. Sedik, and D. M. Ferriero, “Strain-related
brain injury in neonatal mice subjected to hypoxia- ischemia,”
Brain Research, vol. 810, no. 1-2, pp. 114–122, 1998.
[24] S. S. Martin, J. R. Perez-Polo, K. M. Noppens, and M. R.
Grafe, “Biphasic changes in the levels of poly(ADP-ribose)
polymerase-1 and caspase 3 in the immature brain following
hypoxia-ischemia,” International Journal of Developmental Neu-
roscience, vol. 23, no. 8, pp. 673–686, 2005.
[25] L. D. McCullough, Z. Zeng, K. K. Blizzard, I. Debchoudhury,
and P. D. Hurn, “Ischemic nitric oxide and poly (ADP-ribose)
polymerase-1 in cerebral ischemia: Male toxicity, female protec-
tion,” Journal of Cerebral Blood Flow andMetabolism, vol. 25, no.
4, pp. 502–512, 2005.
[26] M. Yuan, C. Siegel, Z. Zeng, J. Li, F. Liu, and L. D. McCullough,
“Sex differences in the response to activation of the poly
(ADP-ribose) polymerase pathway after experimental stroke,”
Experimental Neurology, vol. 217, no. 1, pp. 210–218, 2009.
[27] J. C. Burnsed, R. Chavez-Valdez, M. S. Hossain et al., “Hypoxia-
ischemia and therapeutic hypothermia in the neonatal mouse
brain - A longitudinal study,” PLoS ONE, vol. 10, no. 3, Article
ID e0118889, 2015.
[28] C. M. Traudt, R. J. McPherson, L. A. Bauer et al., “Concurrent
erythropoietin and hypothermia treatment improve outcomes
in a term nonhuman primate model of perinatal asphyxia,”
Developmental Neuroscience, vol. 35, no. 6, pp. 491–503, 2013.
[29] C. Zhu, X. Wang, X. Cheng et al., “Post-ischemic hypothermia-
induced tissue protection and diminished apoptosis after
neonatal cerebral hypoxia-ischemia,” Brain Research, vol. 996,
no. 1, pp. 67–75, 2004.
[30] T. G. Demarest and M. M. McCarthy, “Sex differences in
mitochondrial (dys)function: Implications for neuroprotec-
tion,” Journal of Bioenergetics and Biomembranes, vol. 47, no. 1-2,
pp. 173–188, 2014.
[31] B. S. Reinboth, C. Ko¨ster, H. Abberger et al., “Endogenous
hypothermic response to hypoxia reduces brain injury: Impli-
cations for modeling hypoxic-ischemic encephalopathy and
therapeutic hypothermia in neonatal mice,” Experimental Neu-
rology, vol. 283, pp. 264–275, 2016.
[32] H. Sabir, E. Scull-Brown, X. Liu, and M. Thoresen, “Immedi-
ate hypothermia is not neuroprotective after severe hypoxia-
ischemia and is deleterious when delayed by 12 hours in
neonatal rats,” Stroke, vol. 43, no. 12, pp. 3364–3370, 2012.
[33] A. Y. Fang, F. F. Gonzalez, R. A. Sheldon, and D. M. Fer-
riero, “Effects of combination therapy using hypothermia and
erythropoietin in a rat model of neonatal hypoxia-ischemia,”
Pediatric Research, vol. 73, no. 1, pp. 12–17, 2013.
[34] H. Sabir, D. Osredkar, E. Maes, T. Wood, and M. Thoresen,
“Xenon combined with therapeutic hypothermia is not neuro-
protective after severe hypoxia-ischemia in neonatal rats,” PLoS
ONE, vol. 11, no. 6, Article ID e0156759, 2016.
[35] M. Thoresen, C. E. Hobbs, T. Wood, E. Chakkarapani, and J.
Dingley, “Cooling combined with immediate or delayed xenon
inhalation provides equivalent long-term neuroprotection after
neonatal hypoxia-ischemia,” Journal of Cerebral Blood Flow and
Metabolism, vol. 29, no. 4, pp. 707–714, 2009.
[36] P. Ferrazzano, V. Chanana, K. Uluc et al., “Age-dependent
microglial activation in immature brains after hypoxia-
ischemia,” CNS and Neurological Disorders - Drug Targets, vol.
12, no. 3, pp. 338–349, 2013.
[37] Y. Carlsson, X.Wang, L. Schwendimann et al., “Combined effect
of hypothermia and caspase-2 gene deficiency on neonatal
hypoxic-ischemic brain injury,” Pediatric Research, vol. 71, no.
5, pp. 566–572, 2012.
[38] L. Giovannelli, A. Cozzi, I. Guarnieri et al., “Comet Assay as a
Novel Approach for Studying DNA Damage in Focal Cerebral
Ischemia: Differential Effects of NMDA Receptor Antagonists
BioMed Research International 11
and Poly(ADP-Ribose) Polymerase Inhibitors,” Journal of Cere-
bral Blood Flow &Metabolism, vol. 22, no. 6, pp. 697–704, 2002.
[39] R. I. Mart´ınez-Zamudio and H. C. Ha, “PARP1 enhances
inflammatory cytokine expression by alteration of promoter
chromatin structure in microglia,” Brain and Behavior, vol. 4,
no. 4, pp. 552–565, 2014.
[40] T. M. Kauppinen, L. Gan, and R. A. Swanson, “Poly(ADP-
ribose) polymerase-1-induced NAD+ depletion promotes
nuclear factor-𝜅B transcriptional activity by preventing p65
de-acetylation,” Biochimica et Biophysica Acta - Molecular Cell
Research, vol. 1833, no. 8, pp. 1985–1991, 2013.
[41] T. Chen, W. Wang, J.-R. Li et al., “PARP inhibition attenuates
early brain injury through NF-𝜅B/MMP-9 pathway in a rat
model of subarachnoid hemorrhage,” Brain Research, vol. 1644,
pp. 32–38, 2016.
[42] U. Cikla, V. Chanana, D. B. Kintner et al., “Suppression of
microglia activation after hypoxia-ischemia results in age-
dependent improvements in neurologic injury,” Journal of
Neuroimmunology, vol. 291, pp. 18–27, 2016.
[43] H. Hagberg, C. Mallard, D. M. Ferriero et al., “The role
of inflammation in perinatal brain injury,” Nature Reviews
Neurology, vol. 11, no. 4, pp. 192–208, 2015.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
